JPWO2023068226A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023068226A5 JPWO2023068226A5 JP2023554675A JP2023554675A JPWO2023068226A5 JP WO2023068226 A5 JPWO2023068226 A5 JP WO2023068226A5 JP 2023554675 A JP2023554675 A JP 2023554675A JP 2023554675 A JP2023554675 A JP 2023554675A JP WO2023068226 A5 JPWO2023068226 A5 JP WO2023068226A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021170114 | 2021-10-18 | ||
| PCT/JP2022/038604 WO2023068226A1 (ja) | 2021-10-18 | 2022-10-17 | 抗ｃｄ３７抗体－薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023068226A1 JPWO2023068226A1 (https=) | 2023-04-27 |
| JPWO2023068226A5 true JPWO2023068226A5 (https=) | 2024-06-28 |
Family
ID=86059233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554675A Pending JPWO2023068226A1 (https=) | 2021-10-18 | 2022-10-17 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12138315B2 (https=) |
| EP (1) | EP4420683A1 (https=) |
| JP (1) | JPWO2023068226A1 (https=) |
| KR (1) | KR20240099178A9 (https=) |
| CN (1) | CN118119408A (https=) |
| AU (1) | AU2022368385A1 (https=) |
| CA (1) | CA3235358A1 (https=) |
| CO (1) | CO2024003299A2 (https=) |
| IL (1) | IL312237A (https=) |
| MX (1) | MX2024004048A (https=) |
| TW (1) | TW202330041A (https=) |
| WO (1) | WO2023068226A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4699622A1 (en) * | 2023-04-19 | 2026-02-25 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and other medicine |
| EP4737483A1 (en) | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| AU2024362226A1 (en) | 2023-10-18 | 2026-03-05 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
| CN117264072B (zh) * | 2023-11-22 | 2024-03-22 | 江苏迈威康新药研发有限公司 | 一种抗sn38单抗及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| RU2423381C2 (ru) * | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| CA2858964A1 (en) | 2011-12-13 | 2013-06-20 | Nordic Nanovector As | Chimeric therapeutic anti-cd37 antibodie hh1 |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2015017552A1 (en) * | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| CN116059395A (zh) * | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| SG11202100653YA (en) * | 2018-07-25 | 2021-02-25 | Daiichi Sankyo Co Ltd | Effective method for manufacturing antibody-drug conjugate |
-
2022
- 2022-10-17 KR KR1020247012280A patent/KR20240099178A9/ko active Pending
- 2022-10-17 CA CA3235358A patent/CA3235358A1/en active Pending
- 2022-10-17 EP EP22883530.2A patent/EP4420683A1/en active Pending
- 2022-10-17 WO PCT/JP2022/038604 patent/WO2023068226A1/ja not_active Ceased
- 2022-10-17 IL IL312237A patent/IL312237A/en unknown
- 2022-10-17 TW TW111139216A patent/TW202330041A/zh unknown
- 2022-10-17 AU AU2022368385A patent/AU2022368385A1/en active Pending
- 2022-10-17 MX MX2024004048A patent/MX2024004048A/es unknown
- 2022-10-17 CN CN202280070329.8A patent/CN118119408A/zh active Pending
- 2022-10-17 JP JP2023554675A patent/JPWO2023068226A1/ja active Pending
-
2024
- 2024-01-12 US US18/411,436 patent/US12138315B2/en active Active
- 2024-03-18 CO CONC2024/0003299A patent/CO2024003299A2/es unknown
- 2024-10-07 US US18/907,786 patent/US20250025571A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023068226A5 (https=) | ||
| KR101895047B1 (ko) | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 | |
| JP4137183B2 (ja) | 薬物複合体 | |
| KR102092025B1 (ko) | 페길화된 옥신토모둘린 변이체 | |
| JP7761557B2 (ja) | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 | |
| JP2021100937A5 (https=) | ||
| IL260310B2 (en) | Long-term coupling of a triple agonist to glucagon/GLP–1/GIP receptors | |
| CA2163227A1 (en) | Vitamin b12 mediated oral delivery systems for gcsf and epo | |
| JP2016501204A5 (https=) | ||
| JP2014518209A (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| CN105229025B (zh) | 位点特异性胰岛素缀合物 | |
| KR20120043205A (ko) | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?２（ｇｌｐ?２）약물 결합체 | |
| JP2024507795A (ja) | グルカゴン様ペプチド－１受容体アンタゴニスト | |
| JP2009540842A5 (https=) | ||
| JP2023526550A (ja) | Ｇｌｐ－２の持続型結合体の液状製剤 | |
| KR20210124071A (ko) | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 | |
| KR20180014754A (ko) | 페길화된 옥신토모둘린 변이체 | |
| RU2024113218A (ru) | Конъюгат антитело против cd37-лекарственное средство | |
| EP4302776A1 (en) | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome | |
| JP2024527220A5 (https=) | ||
| JP2025525217A (ja) | グルカゴン様ペプチド－１受容体アンタゴニスト | |
| RU2860341C2 (ru) | Комбинированная терапия инсулинотропным пептидом и glp-2 для предупреждения или лечения синдрома короткой кишки | |
| EP4512414A1 (en) | Combination therapy of glp-2 with insulinotropic peptide, tnf? inhibitor or both for preventing or treating intestinal diseases | |
| JP7723686B2 (ja) | 液状製剤 | |
| KR20210082120A (ko) | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 |